Recognition and treatment of iron overload.
D000328:Adult; D001788:Blood Grouping and Crossmatching; D001815:Bloodletting; D003365:Costs and Cost Analysis; D003676:Deferoxamine / Q000627:therapeutic use; D005029:Ethylenediamines / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D006432:Hemochromatosis / Q000235:genetics / Q000628:therapy; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism; D008297:Male; D013789:Thalassemia / Q000378:metabolism; D014168:Transferrin / Q000378:metabolism; D065227:Transfusion Reaction
D005029:Ethylenediamines; D007502:Iron Chelating Agents; D014168:Transferrin; C011813:ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid); D005293:Ferritins; D007501:Iron; D003676:Deferoxamine